Corcept Therapeutics Inc (CORT) Stock Analysis and Metrics

Corcept Therapeutics

NASDAQ: CORT

$95.33 ▼ -1.33 (-1.38%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap9.99 Bn

P/E213.96

P/S12.98

Div. Yield0.00

Revenue Growth (1y) (Qtr)4.89

Add ratio to table…

About

Corcept Therapeutics Inc is a commercial stage company focused on the discovery and development of medications that modulate the effects of the hormone cortisol to treat severe endocrinologic oncologic metabolic and neurologic disorders. The firm’s lead product Korlym is approved for the treatment of hypercortisolism also known as Cushing’s syndrome in the United States. In addition Corcept is advancing a pipeline of selective cortisol modulators such as relacorilant nenocorilant miricorilant and dazucorilant for indications including solid tumors metabolic associated steatohepatitis amyotrophic lateral sclerosis and other serious conditions.

Corcept generates revenue primarily from the sale of Korlym and its authorized generic version in the United States. The company promotes its products through a dedicated sales force that calls on physicians who treat patients with hypercortisolism. Revenue is also supported by patient assistance programs that help individuals afford therapy and by distribution arrangements with specialty pharmacy providers. All product sales are denominated in US dollars and reflect demand from healthcare providers prescribing the approved indications.

Corcept occupies a niche position within the pharmaceutical industry as a developer of cortisol modulating therapies. Its main competitors in the hypercortisolism market include Recordati’s Signifor Xeris’s Recorlev and Isturisa as well as generic versions of Korlym offered by Teva. The company’s competitive advantage stems from its portfolio of selective cortisol modulators that bind the glucocorticoid receptor without affecting the progesterone receptor thereby avoiding side effects such as endometrial thickening and vaginal bleeding. Additionally Corcept benefits from orphan drug designations for several of its pipeline assets which provide tax credits reduced fees and periods of market exclusivity upon approval.

Corcept serves physicians who treat patients with hypercortisolism solid tumors metabolic liver disease and amyotrophic lateral sclerosis. The company’s customers include endocrinologists oncologists gastroenterologists neurologists and other specialists who prescribe its approved and investigational products. Patients receiving therapy for these conditions represent the ultimate end users of Corcept’s medications.

Investment Thesis

▲ Bull case

Corcept Therapeutics is positioned for substantial long-term growth driven by the expanding addressable market for hypercortisolism treatment, a trend management emphasized but the market may be underestimating. The CATALYST study revealed that one in four patients with difficult-to-control type 2 diabetes has hypercortisolism, a prevalence rate far higher than previously assumed and validated through publication in Diabetes Care. This finding suggests a vast underserved patient population beyond classic Cushing’s syndrome, where screening and treatment rates are accelerating rapidly. Management noted that new prescriber growth has reached record levels for five consecutive quarters and Korlym prescriptions nearly doubled year-over-year in Q1 2025, indicating early-stage adoption in a much larger diabetic cohort. As physician awareness spreads from CATALYST results, which will be highlighted at the ADA Scientific Sessions, the company expects patient identification and treatment to accelerate, directly supporting its $900 million to $950 million 2025 revenue guidance and setting the stage for multi-year expansion. The transition to authorized generic Korlym, while lowering net price per tablet by 13%, is being more than offset by volume growth, with management explicitly stating that increased tablet shipments will overwhelm any price-related headwinds—a dynamic already reflected in their full-year outlook.
The impending FDA approval of relacorilant for Cushing’s syndrome represents a near-term catalyst with significant upside potential that exceeds current market expectations. Corcept resubmitted its NDA for relacorilant following FDA feedback, with a PDUFA date expected six months post-resubmission—positioning approval for late Q4 2025 or early Q1 2026. Relacorilant demonstrates superior efficacy and safety versus Korlym, with consistent improvements across hypercortisolism symptoms including hypertension, hyperglycemia, weight, lean muscle mass, waist circumference, cognition, and quality of life, all maintained long-term as shown in extension studies where some patients received treatment for over six years. Crucially, relacorilant avoids serious adverse effects associated with Korlym, such as hypokalemia, endometrial hypertrophy, vaginal bleeding, adrenal insufficiency, and QT prolongation, giving it a markedly better risk-benefit profile. Sean Maduck projected relacorilant could generate $3 billion to $5 billion annually in hypercortisolism alone within three to five years—a figure that dwarfs current Korlym sales and implies a multi-fold expansion of the addressable market once the drug achieves standard-of-care status. The absence of an anticipated advisory committee meeting reduces regulatory uncertainty and accelerates the path to launch.
Corcept’s oncology franchise, anchored by Lifyorli (relacorilant) plus nab-paclitaxel, offers a durable and scalable growth engine beyond hypercortisolism, with recent ASCO 2026 data revealing deeper value than initially appreciated. The ROSELLA trial showed a 35% reduction in the risk of death (HR: 0.65; p=0.0004) and median overall survival of 16.0 months versus 11.9 months for nab-paclitaxel alone—a meaningful improvement over the previously cited 30% PFS benefit. This survival advantage was consistent across all prespecified subgroups, including patients with recent taxane exposure and those without biomarker selection, reinforcing relacorilant’s broad applicability in platinum-resistant ovarian cancer. With FDA approval secured in March 2026 and inclusion in NCCN Guidelines as a preferred regimen, Lifyorli is rapidly becoming standard-of-care, creating a foundation for label expansions. Corcept is advancing the BELLA study to evaluate relacorilant with nab-paclitaxel and bevacizumab in earlier lines of ovarian cancer, while exploring combinations in endometrial, cervical, pancreatic, and prostate cancers—particularly where cortisol-mediated resistance undermines androgen deprivation therapy or immunotherapy. The company’s proprietary pipeline, including dazucorilant for ALS (with intriguing long-term survival signals) and miricorilant for MASH (showing 30% liver fat reduction in Phase 1b), provides additional optionality. Management’s commitment to building a standalone oncology division and pursuing regulatory engagement for dazucorilant based on exploratory survival data (HR: 0.16, p=0.0009) signals confidence in broadening the cortisol modulation platform across high-unmet-need indications.

Corcept Therapeutics is positioned for substantial long-term growth driven by the expanding addressable market for hypercortisolism treatment, a trend management emphasized but the market may be underestimating. The CATALYST study revealed that one in four patients with difficult-to-control type 2 diabetes has hypercortisolism, a prevalence rate far higher than previously assumed and validated through publication in Diabetes Care. This finding suggests a vast underserved patient population beyond classic Cushing’s syndrome, where screening and treatment rates are accelerating rapidly. Management noted that new prescriber growth has reached record levels for five consecutive quarters and Korlym prescriptions nearly doubled year-over-year in Q1 2025, indicating early-stage adoption in a much larger diabetic cohort. As physician awareness spreads from CATALYST results, which will be highlighted at the ADA Scientific Sessions, the company expects patient identification and treatment to accelerate, directly supporting its $900 million to $950 million 2025 revenue guidance and setting the stage for multi-year expansion. The transition to authorized generic Korlym, while lowering net price per tablet by 13%, is being more than offset by volume growth, with management explicitly stating that increased tablet shipments will overwhelm any price-related headwinds—a dynamic already reflected in their full-year outlook.
The impending FDA approval of relacorilant for Cushing’s syndrome represents a near-term catalyst with significant upside potential that exceeds current market expectations. Corcept resubmitted its NDA for relacorilant following FDA feedback, with a PDUFA date expected six months post-resubmission—positioning approval for late Q4 2025 or early Q1 2026. Relacorilant demonstrates superior efficacy and safety versus Korlym, with consistent improvements across hypercortisolism symptoms including hypertension, hyperglycemia, weight, lean muscle mass, waist circumference, cognition, and quality of life, all maintained long-term as shown in extension studies where some patients received treatment for over six years. Crucially, relacorilant avoids serious adverse effects associated with Korlym, such as hypokalemia, endometrial hypertrophy, vaginal bleeding, adrenal insufficiency, and QT prolongation, giving it a markedly better risk-benefit profile. Sean Maduck projected relacorilant could generate $3 billion to $5 billion annually in hypercortisolism alone within three to five years—a figure that dwarfs current Korlym sales and implies a multi-fold expansion of the addressable market once the drug achieves standard-of-care status. The absence of an anticipated advisory committee meeting reduces regulatory uncertainty and accelerates the path to launch.
Corcept’s oncology franchise, anchored by Lifyorli (relacorilant) plus nab-paclitaxel, offers a durable and scalable growth engine beyond hypercortisolism, with recent ASCO 2026 data revealing deeper value than initially appreciated. The ROSELLA trial showed a 35% reduction in the risk of death (HR: 0.65; p=0.0004) and median overall survival of 16.0 months versus 11.9 months for nab-paclitaxel alone—a meaningful improvement over the previously cited 30% PFS benefit. This survival advantage was consistent across all prespecified subgroups, including patients with recent taxane exposure and those without biomarker selection, reinforcing relacorilant’s broad applicability in platinum-resistant ovarian cancer. With FDA approval secured in March 2026 and inclusion in NCCN Guidelines as a preferred regimen, Lifyorli is rapidly becoming standard-of-care, creating a foundation for label expansions. Corcept is advancing the BELLA study to evaluate relacorilant with nab-paclitaxel and bevacizumab in earlier lines of ovarian cancer, while exploring combinations in endometrial, cervical, pancreatic, and prostate cancers—particularly where cortisol-mediated resistance undermines androgen deprivation therapy or immunotherapy. The company’s proprietary pipeline, including dazucorilant for ALS (with intriguing long-term survival signals) and miricorilant for MASH (showing 30% liver fat reduction in Phase 1b), provides additional optionality. Management’s commitment to building a standalone oncology division and pursuing regulatory engagement for dazucorilant based on exploratory survival data (HR: 0.16, p=0.0009) signals confidence in broadening the cortisol modulation platform across high-unmet-need indications.

▼ Bear case

Corcept Therapeutics faces significant near-term revenue pressure from the ongoing shift to its authorized generic Korlym, a trend management acknowledged but may be underestimating in its impact on profitability and pricing power. Sean Maduck confirmed that over half of patients are now on the authorized generic, with that percentage expected to rise throughout 2025, directly eroding average net price per tablet by 13% year-over-year in Q1 2025. While management argues volume growth will overwhelm this price decline, the pharmacy vendor constraints experienced in Q1 2025—where operational failures suppressed January and February results despite strong underlying demand—raise concerns about whether the supply chain can scale sufficiently to deliver the volume needed to offset pricing pressure. The company’s reliance on a restricted distribution network due to Korlym’s mifepristone content creates a structural bottleneck; although relacorilant may enable broader dispensing, Korlym’s current limitations persist. If volume growth fails to accelerate as expected—particularly if CATALYST-driven screening does not translate to sustained prescribing—revenue could fall short of the $900 million to $950 million guidance, especially given that Q1 results did not reflect the claimed business strength due to these very issues. The authorization of generic competition introduces long-term margin compression risk, as payers will continue to favor lower-net-cost options, limiting Corcept’s ability to maintain pricing power even with volume gains.
The commercial launch of relacorilant for Cushing’s syndrome faces adoption hurdles that could delay or diminish its revenue contribution, despite management’s optimistic projections. While relacorilant demonstrates improved efficacy and safety, Korlym remains an established, effective therapy with two decades of real-world use, and switching inertia among physicians and patients may slow uptake, particularly if relacorilant’s pricing or reimbursement terms are not markedly advantageous. Management did not address potential rebate or formulary pressures that could limit access, nor did they clarify how relacorilant will be positioned versus Korlym in treatment algorithms—whether as a first-line alternative, later-line option, or premium-priced specialty product. The expectation that relacorilant could reach $3 billion to $5 billion in annual sales assumes rapid and widespread adoption across a vastly expanded patient base, but hypercortisolism diagnosis remains complex, requiring nuanced screening that many primary care providers may not routinely perform even after CATALYST awareness. Without a corresponding increase in diagnostic rates—beyond just physician education—patient identification may not keep pace with drug availability, creating a ceiling on addressable demand. Furthermore, the FDA’s request for additional NDA analyses prior to resubmission suggests residual concerns about the original application, and while management expressed confidence, any delay beyond the expected six-month PDUFA timeline could push meaningful revenue contribution into 2027, undermining near-term growth narratives.
Corcept’s oncology expansion, while scientifically promising, carries substantial execution and competitive risks that could limit the translational success of relacorilant beyond ovarian cancer. The ROSELLA trial, though positive, enrolled a heavily pretreated patient population with platinum-resistant disease, and it remains unproven whether relacorilant combinations will show similar benefit in earlier lines of therapy or in tumors with lower glucocorticoid receptor dependency. The BELLA study, which adds bevacizumab to nab-paclitaxel and relacorilant, increases complexity and cost, and there is no guarantee that triplet regimens will improve outcomes sufficiently to justify added toxicity and expense over existing doublets or emerging immunotherapies. In prostate cancer, the rationale for combining relacorilant with enzalutamide depends on cortisol-mediated resistance mechanisms, but clinical validation in the University of Chicago-led Phase 2 trial is still pending, and failure to show benefit would undermine a key pipeline pillar. Similarly, the ALS program with dazucorilant failed its primary endpoint (ALSFRS-R), and while exploratory survival data (HR: 0.16, p=0.0009) is intriguing, it stems from a post-hoc analysis in a long-term extension study—subject to selection bias and not sufficient for regulatory approval without confirmatory trials. The MASH initiative with miricorilant, though mechanistically sound, faces intense competition from established pathways (e.g., FXR agonists, THR-β agonists) and late-stage candidates with larger datasets. Corcept’s broad pipeline diversification increases optionality but also spreads R&D focus, and without near-term clinical readouts in multipleindications, the market may grow skeptical of the company’s ability to translate cortisol modulation into multiple blockbuster franchises beyond its current niche successes.

Corcept Therapeutics faces significant near-term revenue pressure from the ongoing shift to its authorized generic Korlym, a trend management acknowledged but may be underestimating in its impact on profitability and pricing power. Sean Maduck confirmed that over half of patients are now on the authorized generic, with that percentage expected to rise throughout 2025, directly eroding average net price per tablet by 13% year-over-year in Q1 2025. While management argues volume growth will overwhelm this price decline, the pharmacy vendor constraints experienced in Q1 2025—where operational failures suppressed January and February results despite strong underlying demand—raise concerns about whether the supply chain can scale sufficiently to deliver the volume needed to offset pricing pressure. The company’s reliance on a restricted distribution network due to Korlym’s mifepristone content creates a structural bottleneck; although relacorilant may enable broader dispensing, Korlym’s current limitations persist. If volume growth fails to accelerate as expected—particularly if CATALYST-driven screening does not translate to sustained prescribing—revenue could fall short of the $900 million to $950 million guidance, especially given that Q1 results did not reflect the claimed business strength due to these very issues. The authorization of generic competition introduces long-term margin compression risk, as payers will continue to favor lower-net-cost options, limiting Corcept’s ability to maintain pricing power even with volume gains.
The commercial launch of relacorilant for Cushing’s syndrome faces adoption hurdles that could delay or diminish its revenue contribution, despite management’s optimistic projections. While relacorilant demonstrates improved efficacy and safety, Korlym remains an established, effective therapy with two decades of real-world use, and switching inertia among physicians and patients may slow uptake, particularly if relacorilant’s pricing or reimbursement terms are not markedly advantageous. Management did not address potential rebate or formulary pressures that could limit access, nor did they clarify how relacorilant will be positioned versus Korlym in treatment algorithms—whether as a first-line alternative, later-line option, or premium-priced specialty product. The expectation that relacorilant could reach $3 billion to $5 billion in annual sales assumes rapid and widespread adoption across a vastly expanded patient base, but hypercortisolism diagnosis remains complex, requiring nuanced screening that many primary care providers may not routinely perform even after CATALYST awareness. Without a corresponding increase in diagnostic rates—beyond just physician education—patient identification may not keep pace with drug availability, creating a ceiling on addressable demand. Furthermore, the FDA’s request for additional NDA analyses prior to resubmission suggests residual concerns about the original application, and while management expressed confidence, any delay beyond the expected six-month PDUFA timeline could push meaningful revenue contribution into 2027, undermining near-term growth narratives.
Corcept’s oncology expansion, while scientifically promising, carries substantial execution and competitive risks that could limit the translational success of relacorilant beyond ovarian cancer. The ROSELLA trial, though positive, enrolled a heavily pretreated patient population with platinum-resistant disease, and it remains unproven whether relacorilant combinations will show similar benefit in earlier lines of therapy or in tumors with lower glucocorticoid receptor dependency. The BELLA study, which adds bevacizumab to nab-paclitaxel and relacorilant, increases complexity and cost, and there is no guarantee that triplet regimens will improve outcomes sufficiently to justify added toxicity and expense over existing doublets or emerging immunotherapies. In prostate cancer, the rationale for combining relacorilant with enzalutamide depends on cortisol-mediated resistance mechanisms, but clinical validation in the University of Chicago-led Phase 2 trial is still pending, and failure to show benefit would undermine a key pipeline pillar. Similarly, the ALS program with dazucorilant failed its primary endpoint (ALSFRS-R), and while exploratory survival data (HR: 0.16, p=0.0009) is intriguing, it stems from a post-hoc analysis in a long-term extension study—subject to selection bias and not sufficient for regulatory approval without confirmatory trials. The MASH initiative with miricorilant, though mechanistically sound, faces intense competition from established pathways (e.g., FXR agonists, THR-β agonists) and late-stage candidates with larger datasets. Corcept’s broad pipeline diversification increases optionality but also spreads R&D focus, and without near-term clinical readouts in multipleindications, the market may grow skeptical of the company’s ability to translate cortisol modulation into multiple blockbuster franchises beyond its current niche successes.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password